Breaking News Instant updates and real-time market news.

MACK

Merrimack

$5.66

0.18 (3.28%)

07:33
10/11/16
10/11
07:33
10/11/16
07:33

Merrimack reports final results of Phase 3 NAPOLI-1 study of ONIVYDE

Merrimack Pharmaceuticals announced final results from the pivotal Phase 3 NAPOLI-1 study validating the use of ONIVYDE in combination with fluorouracil and leucovorin, which represents a new standard of care for patients with metastatic pancreatic ductal adenocarcinoma following treatment with gemcitabine-based therapy. The final NAPOLI-1 results were presented in a poster discussion session and a separate analysis of NAPOLI-1 safety-over-time data was presented in a poster session at the European Society for Medical Oncology 2016 Congress in Copenhagen. "The final results of the NAPOLI-1 study provide a high level of clinical evidence establishing the ONIVYDE regimen as a meaningful treatment option for patients with metastatic pancreatic cancer," said Prof. Li-Tzong Chen, M.D., Ph.D., corresponding author, Investigator on the NAPOLI-1 trial and Director, National Institute of Cancer Research, National Health Research Institutes in Tainan, Taiwan. "Pancreatic cancer is a devastating disease with a poor prognosis. In a patient population with few treatment options, the ONIVYDE regimen provides an opportunity for extended overall survival while maintaining baseline quality-of-life and represents a new standard of care. We thank all of the patients, caregivers and investigators who participated in this pivotal study." The extended data cutoff occurred at final database lock in November 2015 after 382 OS events that had occurred in the intention-to-treat (ITT) population. In this extended analysis of NAPOLI-1, the previously described overall survival advantage was maintained for ONIVYDE in combination with 5-FU and leucovorin versus 5-FU and leucovorin alone: 6.2 months versus 4.2 months (p=0.039, hazard ratio (HR) =0.75, 95% CI: [.057 - .99]). Findings also showed that one in four patients treated with the ONIVYDE combination regimen survived one year or more, a significant milestone. This was represented by a 26% probability of survival at one year for patients receiving ONIVYDE in combination with 5-FU and leucovorin versus 16% for patients who received 5-FU and leucovorin alone. Furthermore, disease control was achieved in twice as many patients treated with ONIVYDE in combination with 5-FU and leucovorin (52%) compared to 5-FU and leucovorin alone (24%). The demonstrated improvements in overall survival for the ONIVYDE combination regimen were achieved with little or no impact on quality of life over 12 weeks despite the addition of a second chemotherapeutic agent to 5-FU and leucovorin, a therapy recognized as a well-managed treatment for metastatic pancreatic cancer. Results from a separate analysis of the NAPOLI-1 data evaluating the incidence and prevalence of gastrointestinal toxicities and neutropenia during the course of treatment with ONIVYDE plus 5-FU and leucovorin showed that the majority of these adverse events occurred early in treatment with decreased incidence and severity thereafter. Dose reductions or dose delays were commonly used to manage these adverse events and may account for the decreased incidence and/or severity that was observed.

MACK Merrimack
$5.66

0.18 (3.28%)

08/05/16
BMUR
08/05/16
NO CHANGE
Target $13
BMUR
Buy
Merrimack price target lowered to $13 from $16 at Brean Capital
Brean Capital lowered its price target on Merrimack to $13 from $16 following Q2 results. The firm cited the sales miss on Onivyde, although they are encouraged by its early launch. Brean Capital reiterated its Buy rating on Merrimack shares.
08/05/16
COWN
08/05/16
DOWNGRADE
COWN
Market Perform
Merrimack downgraded to Market Perform from Outperform at Cowen
08/19/16
BTIG
08/19/16
INITIATION
BTIG
Neutral
Merrimack initiated with a Neutral at BTIG
BTIG analyst Ling Wang initiated Merrimack with a Neutral as he expects shares to be range-bound given the likely slow ramp-up of ONIVYDE and data from MM-302 and MM-121 won't be available until 2017 or beyond;
10/07/16
JPMS
10/07/16
DOWNGRADE
Target $7
JPMS
Neutral
Merrimack downgraded to Neutral from Overweight at JPMorgan
JPMorgan analyst Anupam Rama downgraded Merrimack Pharmaceuticals to Neutral saying the shares are likely to be range-bound after rallying 36% from the 52-week low on September 20. Key pipeline catalysts aren't likely until Q2 of 2017 and beyond while 2016 estimates are not "meaningfully beatable," Rama tells investors in a research note. He lowered his price target for the shares to $7 from $8.

TODAY'S FREE FLY STORIES

DGX

Quest Diagnostics

$110.14

0.44 (0.40%)

, WMT

Wal-Mart

$75.59

0.75 (1.00%)

15:12
06/26/17
06/26
15:12
06/26/17
15:12
Recommendations
Quest Diagnostics, Wal-Mart analyst commentary  »

Raymond James positive on…

DGX

Quest Diagnostics

$110.14

0.44 (0.40%)

WMT

Wal-Mart

$75.59

0.75 (1.00%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 30

    Jul

NOV

National Oilwell

$31.84

0.2 (0.63%)

15:10
06/26/17
06/26
15:10
06/26/17
15:10
Options
Notable call writing in National Oilwell »

Notable call writing in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 28

    Jul

VTR

Ventas

$71.94

0.215 (0.30%)

15:07
06/26/17
06/26
15:07
06/26/17
15:07
Conference/Events
Ventas management to meet with RBC Capital »

Meeting to be held in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 26

    Jun

MU

Micron

$32.50

0.765 (2.41%)

15:05
06/26/17
06/26
15:05
06/26/17
15:05
Options
Micron call volume above normal and directionally bullish »

Bullish option flow…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 26

    Jun

  • 29

    Jun

  • 29

    Aug

MAR

Marriott

$104.06

0.17 (0.16%)

15:00
06/26/17
06/26
15:00
06/26/17
15:00
Conference/Events
Marriott management to meet with RBC Capital »

Meetings to be held in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 26

    Jun

AAPL

Apple

$146.28

0.65 (0.45%)

, HTZ

Hertz

$10.92

1.38 (14.47%)

14:54
06/26/17
06/26
14:54
06/26/17
14:54
Periodicals
Apple only leasing six cars from Hertz, CNBC says »

After Bloomberg reported…

AAPL

Apple

$146.28

0.65 (0.45%)

HTZ

Hertz

$10.92

1.38 (14.47%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 26

    Jun

NG

NovaGold

$4.50

-0.075 (-1.64%)

14:49
06/26/17
06/26
14:49
06/26/17
14:49
Options
NovaGold options imply 6.4% move in share price post-earnings, above median historical move »

Pre-earnings options…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 27

    Jun

AAPL

Apple

$146.28

0.65 (0.45%)

, HTZ

Hertz

$10.84

1.3002 (13.63%)

14:47
06/26/17
06/26
14:47
06/26/17
14:47
Periodicals
Hertz to manage small self-driving car fleet for Apple, Bloomberg says »

Apple (AAPL) is leasing a…

AAPL

Apple

$146.28

0.65 (0.45%)

HTZ

Hertz

$10.84

1.3002 (13.63%)

GOOG

Alphabet

$965.59

8.5 (0.89%)

GOOGL

Alphabet Class A

$986.09

9.47 (0.97%)

CAR

Avis Budget

$24.24

1.23 (5.35%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 26

    Jun

  • 28

    Jun

  • 28

    Jun

  • 19

    Jul

OTIC

Otonomy

$18.75

1 (5.63%)

14:46
06/26/17
06/26
14:46
06/26/17
14:46
Conference/Events
Otonomy to hold a breakfast meeting »

Chief Scientific Officer…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

DGX

Quest Diagnostics

$110.05

0.345 (0.31%)

, WMT

Wal-Mart

$75.61

0.77 (1.03%)

14:44
06/26/17
06/26
14:44
06/26/17
14:44
Hot Stocks
Quest Diagnostics, Wal-Mart team up to offer healthcare services »

Quest Diagnostics (DGX)…

DGX

Quest Diagnostics

$110.05

0.345 (0.31%)

WMT

Wal-Mart

$75.61

0.77 (1.03%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 30

    Jul

EBSB

Meridian Bancorp

14:43
06/26/17
06/26
14:43
06/26/17
14:43
Upgrade
Meridian Bancorp rating change  »

Meridian Bancorp upgraded…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

AMD

AMD

$14.17

-0.21 (-1.46%)

, INTC

Intel

$34.19

-0.17 (-0.49%)

14:43
06/26/17
06/26
14:43
06/26/17
14:43
Recommendations
AMD, Intel analyst commentary  »

Goldman reiterates Sell…

AMD

AMD

$14.17

-0.21 (-1.46%)

INTC

Intel

$34.19

-0.17 (-0.49%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 26

    Jun

  • 29

    Aug

KTOV

Kitov Pharmaceuticals

$1.71

-0.01 (-0.58%)

, PRXL

Parexel

$86.80

-0.31 (-0.36%)

14:41
06/26/17
06/26
14:41
06/26/17
14:41
Hot Stocks
Kitov sees formal filing of NDA for KIT-302 by end of Q3 »

Kitov Pharmaceuticals…

KTOV

Kitov Pharmaceuticals

$1.71

-0.01 (-0.58%)

PRXL

Parexel

$86.80

-0.31 (-0.36%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 26

    Jun

RAD

Rite Aid

$3.93

0.8199 (26.36%)

14:40
06/26/17
06/26
14:40
06/26/17
14:40
Options
Heavy trading in RiteAid as shares surge »

Heavy trading in RiteAid…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

14:40
06/26/17
06/26
14:40
06/26/17
14:40
General news
Treasury Action: yields remain slightly lower »

Treasury Action: yields…

EVLV

EVINE Live

$1.04

-0.03 (-2.80%)

14:39
06/26/17
06/26
14:39
06/26/17
14:39
Conference/Events
EVINE Live management to meet with Craig-Hallum »

Meeting to be held in New…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 28

    Jun

  • 29

    Jun

EVLV

EVINE Live

$1.04

-0.03 (-2.80%)

14:38
06/26/17
06/26
14:38
06/26/17
14:38
Conference/Events
EVINE Live management to meet with B. Riley »

Meeting to be held in New…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 28

    Jun

  • 29

    Jun

HTZ

Hertz

$10.19

0.65 (6.81%)

14:36
06/26/17
06/26
14:36
06/26/17
14:36
Technical Analysis
Technical View: Hertz spikes higher, levels to watch »

The shares were last at…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

AMAG

AMAG Pharmaceuticals

$18.35

0.15 (0.82%)

14:36
06/26/17
06/26
14:36
06/26/17
14:36
Recommendations
AMAG Pharmaceuticals analyst commentary  »

AMAG delay for Makena…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

FN

Fabrinet

$45.60

5.58 (13.94%)

14:30
06/26/17
06/26
14:30
06/26/17
14:30
Options
Timely call activity in Fabrinet »

Timely call activity in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 26

    Jun

  • 12

    Jul

  • 13

    Jul

  • 29

    Aug

AAPL

Apple

$146.28

0.65 (0.45%)

, HTZ

Hertz

$10.24

0.7 (7.34%)

14:26
06/26/17
06/26
14:26
06/26/17
14:26
Periodicals
Breaking Periodicals news story on Apple, Hertz »

Hertz to manage small…

AAPL

Apple

$146.28

0.65 (0.45%)

HTZ

Hertz

$10.24

0.7 (7.34%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 26

    Jun

GM

General Motors

$34.49

0.29 (0.85%)

14:25
06/26/17
06/26
14:25
06/26/17
14:25
Conference/Events
General Motors to host a conference call »

EVP & CFO Chuck…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 26

    Jun

  • 25

    Jul

T

AT&T

$38.15

0.2001 (0.53%)

14:20
06/26/17
06/26
14:20
06/26/17
14:20
Options
Calendar call spread in AT&T rolls short position from July to September »

Calendar call spread in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

14:19
06/26/17
06/26
14:19
06/26/17
14:19
General news
Averages mixed but internals strong »

The averages remain mixed…

$NSD

NASDAQ Market Internals

14:17
06/26/17
06/26
14:17
06/26/17
14:17
Technical Analysis
NASDAQ market internals summary »

Volume is above average…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.